These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33418486)

  • 21. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Papadimitriou C; Linardou H; Aravantinos G; Papakostas P; Skarlos D; Kosmidis P; Fountzilas G; Gogas H; Kalofonos C; Dimopoulos AM
    Br J Cancer; 2004 Nov; 91(9):1639-44. PubMed ID: 15494721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
    Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    Chawla SP; Staddon A; Hendifar A; Messam CA; Patwardhan R; Kamel YM
    BMC Cancer; 2013 Mar; 13():121. PubMed ID: 23497336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study.
    Liu Z; Liu C; Yao W; Gao S; Wang J; Zhang P; Ge H
    Anticancer Drugs; 2021 Oct; 32(9):962-968. PubMed ID: 34001702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
    Suppiah R; Wood L; Elson P; Budd GT
    Invest New Drugs; 2006 Nov; 24(6):509-14. PubMed ID: 16791410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Chawla SP; Cranmer LD; Van Tine BA; Reed DR; Okuno SH; Butrynski JE; Adkins DR; Hendifar AE; Kroll S; Ganjoo KN
    J Clin Oncol; 2014 Oct; 32(29):3299-306. PubMed ID: 25185097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.
    Luke JJ; D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Maki RG; de Stanchina E; Musi E; Singer S; Schwartz GK
    Clin Cancer Res; 2012 May; 18(9):2638-47. PubMed ID: 22374332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
    Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
    Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
    Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
    Schliemann C; Hemmerle T; Berdel AF; Angenendt L; Kerkhoff A; Hering JP; Heindel W; Hartmann W; Wardelmann E; Chawla SP; de Braud F; Lenz G; Neri D; Kessler T; Berdel WE
    Eur J Cancer; 2021 Jun; 150():143-154. PubMed ID: 33901793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
    Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
    Leyvraz S; Herrmann R; Guillou L; Honegger HP; Christinat A; Fey MF; Sessa C; Wernli M; Cerny T; Dietrich D; Pestalozzi B;
    Br J Cancer; 2006 Nov; 95(10):1342-7. PubMed ID: 17031396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD
    Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.